Trial Profile
Treatment Optimization of Anti-EGFR Therapy (Cetuximab and Panitumumab) in Patients With Metastatic Colorectal Cancer Based Early 18F-FDG-PET
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Apr 2022
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Panitumumab (Primary) ; Zirconium-89 cetuximab
- Indications Adenocarcinoma; Cancer; Colorectal cancer
- Focus Therapeutic Use
- Acronyms COLO CETUX
- 01 Oct 2019 Status changed from recruiting to completed.
- 13 Aug 2019 Planned number of patients changed from 25 to 150.
- 13 Aug 2019 Status changed to recruiting.